Breeze Meds NAD+ Review: Three Prices, and No Terms of Service

Breeze Meds is better than almost everyone we rank at the two disclosures this industry most often skips, and worse than almost everyone at the two a buyer most needs.

It names all four of its compounding pharmacies, with phone numbers. It names its prescribing physicians and publishes their NPI numbers. Across the field we track, most companies name neither.

Then you try to find out what it costs, and the same page gives you three answers. And you try to find out what happens if you want your money back, and there is no answer at all — because Breeze Meds has no terms of service, no refund policy and no shipping policy anywhere on its website.

What it costs — and the three numbers on one page

We publish $169 a month for the NAD+ injection and $210 for the nasal spray, because those are the two figures that appear both on Breeze's product cards and in the site's own machine-readable product catalogue. Two independent surfaces of the same site, rather than one marketing line, is the strongest corroboration available here.

The rest of what that page says about the price, verbatim and re-read on 8 August 2026:

• •the hero: *"Just $179 to start"*
• •the product card: *"Starting at $169 NAD+ Injection"*
• •the product card: *"Starting at $210 NAD+ Nasal Spray"*
• •the FAQ, further down the same page: *"BreezeMeds NAD+ therapy starts regular at just $249/month, including your medical consultation, prescription, medication, and free shipping"*

Three different numbers for one product, on one page — and only the $249 states a billing period at all. "Starting at $169" does not say per what.

The sermorelin line does the same thing on a smaller scale: the card says $100, the catalogue says $135, and the gap between the two is $35 with nothing on the page to reconcile them.

We are not going to declare which figure is "real". What we can say is which one has two sources behind it, which is why $169 is the number in our comparison — and that a reader should expect the $249 "regular" framing to appear somewhere in their own checkout, because Breeze wrote it into its own FAQ.

One more, on the weight-loss side, because it shows the same habit: Breeze's GLP-1 "bundles" are worse than paying monthly. The three-month semaglutide bundle is $748, which is $249.33 a month against a $199 month-to-month rate. A bundle that costs more is not a saving, and it should not be read as one.

And if you choose a phone or video consultation and then do not proceed, there is an $80 consultation fee.

The missing legal layer

This is the finding that matters most, and it is very simple to check.

`/terms`, `/terms-of-service`, `/privacy-policy`, `/privacy` and `/refund-policy` all return 404. There is no terms of service. There is no published refund policy, no cancellation policy and no shipping policy. The privacy policy exists only as inline text on the home page — not as a document with a URL you could bookmark, cite or compare against a later version.

For a company that takes recurring card payments for prescription medication, that is not a paperwork gap. It is the absence of the document that says what you are owed when something goes wrong: a wrong dose, a delayed shipment, a charge after cancelling, a prescriber declining to prescribe after you have paid. Every other company on our board has something here, even when what it says is unfavourable — Shed buries a two-month minimum in section eleven of its terms, which is worth criticising precisely because there is a section eleven to read.

Breeze also cannot decide what it is called: the inline privacy text says "Breezemeds, LLC, a Delaware corporation" — itself a contradiction, since an LLC is not a corporation — while the consultation footer says "Breezemeds, Inc."

What it is genuinely good at

Four pharmacies, named, with phone numbers. Belmar, Strive, Epiq Scripts and Casa Pharma Rx. Two companies we rank name more — Ageless names seven and Pallas Health names six — and most name none at all.

Two physicians, named, with NPIs. The clinical side runs through Lion MD: Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684). Both verify as active in the federal NPPES registry — we checked, against a fabricated NPI as a control in the same pass.

LegitScript resolves. Breeze's seal ID returns a live record from LegitScript's own server rather than being a self-hosted image linking nowhere, which is what several companies we rank actually have.

Its own enforcement record is clean. We screened the FDA warning-letter index for "breezemeds", "breeze meds" and "Breezemeds, LLC" and every query returned zero, with a known positive control returning in the same pass so the clean is a result rather than a broken search.

Two routes. The injection and a nasal spray — which matters because the nasal route is a genuine alternative for people who will not inject, and roughly half of what we rank sells only the needle.

One thing about the pharmacies worth stating precisely

Naming your suppliers means a reader can check them, and checking is what naming is for. One of Breeze's four, Belmar, has a record: an FDA warning letter issued 31 March 2023 concerning compounding practices, addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy". The FDA closed that letter out on 30 October 2023.

The words "closed out" are not decoration. A closed-out letter is a matter FDA has recorded as resolved, and describing it as open would be a false statement about a real company. We are not going to characterise what the letter alleged either — that is the FDA's document, and paraphrasing an enforcement action turns a public record into a claim of ours.

Breeze itself carries no letter. This is a disclosure about a supplier, and it exists at all only because Breeze named the supplier. A company that names nobody has nothing to check, and that is the worse position, not the better one.

Where the clinical bench actually comes from

Breeze runs on the CareValidate white-label platform, which several other telehealth brands also run on — including two more on our own board. The two physicians Breeze names are the same two that other brands on that backend publish, and the FAQ and product copy is byte-identical across several of them.

None of that makes Breeze fake, and shared infrastructure is normal. What it means practically is that three brands on one backend are one source, not three second opinions — so if you are comparing Breeze against another company and finding the same doctors, the same pharmacies and the same FAQ, that similarity is the platform, not independent agreement.

The claims on its own page that do not stand up

Breeze's NAD+ page publishes efficacy statistics attributed only to "customer surveys" — including "9/10 patients report feeling 10 years younger" — and its results panel renders as broken placeholder counters: "1M % Increase in energy levels", "1 % Improvement in cognitive Function". A number that renders as 1M% is not a number.

Its patient count is inconsistent with itself: "50,000+" on the home page against "100,000+" on the NAD+ page.

And there is a hygiene problem worth naming for a company handling health data: Breeze's client-side configuration ships a Klaviyo private API key and a Supabase URL and key in plaintext to every visitor's browser.

The evidence, which is the same for everyone we rank

Breeze tells patients that "mental clarity and focus often improve by week 3". No trial of either route has ever measured that, or any other timeline.

No rigorous human trial shows that injected or nasal NAD+ improves cognition, focus or energy. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo¹; a second randomised trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit either²; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all³. Our full position is in the NAD+ and brain-fog evidence review.

The compounded preparations Breeze dispenses are also not FDA-approved products, and a compounded drug is not a generic equivalent of an approved one⁴.

The bottom line

Breeze Meds tells you who makes your medicine and who prescribes it, publishes NPIs that verify, carries a LegitScript certification that resolves and has a clean enforcement record of its own. On the disclosures most of this industry avoids, it is near the top of our board.

It also advertises one injection at $169, $179 and $249 on a single page, prices its sermorelin $35 apart from its own catalogue, sells GLP-1 bundles that cost more than paying monthly, and publishes no terms of service, no refund policy and no cancellation policy anywhere at all. You can find out exactly who is involved in your prescription, and nothing whatsoever about what you are owed if it goes wrong.